Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT03516617

Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Led by Mayo Clinic · Updated on 2026-02-09

120

Participants Needed

3

Research Sites

631 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This phase II trials studies how well acalabrutinib with or without obinutuzumab works in treating patients with early-stage chronic lymphocytic leukemia or small lymphocytic lymphoma. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether giving acalabrutinib with or without obinutuzumab will work better in treating patients with early-stage chronic lymphocytic leukemia or small lymphocytic lymphoma.

CONDITIONS

Official Title

Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older
  • Diagnosis of biopsy-proven small lymphocytic lymphoma or chronic lymphocytic leukemia confirmed by specific immune markers
  • No prior treatment for CLL or SLL (except certain non-chemotherapy agents)
  • Testing for prognostic factors according to CLL-IPI done within 730 days before registration
  • High or very high risk by CLL-IPI for Arms A and B; low or intermediate risk for Arm C
  • Eastern Cooperative Oncology Group performance status 0, 1, or 2
  • Willing to provide informed consent and samples for research
  • Able to return for follow-up during active monitoring
  • For Arms A and B: Specific blood counts and liver/kidney function within normal limits
  • Negative pregnancy test for persons who can become pregnant
  • Willing to provide bone marrow aspirate sample for research
Not Eligible

You will not qualify if you...

  • Diagnosis of CLL or SLL more than 24 months before registration
  • Prior use of ibrutinib, BCR inhibitors, or BCL-2 inhibitors
  • Known central nervous system lymphoma or leukemia
  • Indications for chemotherapy such as worsening anemia or thrombocytopenia not caused by autoimmune disease
  • Symptoms like significant weight loss, extreme fatigue, prolonged fever, or night sweats without infection
  • Serious systemic illnesses or diseases interfering with safety assessment
  • Known HIV positive on antiretroviral treatment (unless no immunocompromised state)
  • Uncontrolled infections, heart failure, unstable angina, arrhythmia, or psychiatric/social issues limiting compliance
  • Receiving other investigational agents for primary cancer
  • Other active cancers within 2 years except certain skin, cervical, or prostate cancers
  • Recent heart attack or severe heart conditions
  • For Arms A and B: Pregnancy, nursing, or unwillingness to use effective contraception
  • Active hepatitis B or C infection or positive tests requiring exclusion
  • Recent stroke or brain bleeding
  • Bleeding disorders
  • Use of warfarin or similar anticoagulants within 7 days before study drug
  • Treatment with strong CYP3A inducers
  • Recent gastrointestinal ulcers
  • History of progressive multifocal leukoencephalopathy
  • Live vaccine received within 28 days before randomization

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 3 locations

1

Mayo Clinic in Arizona

Scottsdale, Arizona, United States, 85259

Actively Recruiting

2

Mayo Clinic in Florida

Jacksonville, Florida, United States, 32224-9980

Actively Recruiting

3

Mayo Clinic in Rochester

Rochester, Minnesota, United States, 55905

Actively Recruiting

Loading map...

Research Team

C

Clinical Trials Referral Office

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here